Tango Therapeutics (TNGX) Cash & Current Investments (2020 - 2026)

Tango Therapeutics' Cash & Current Investments history runs 7 years deep, the most recent figure standing at $157.8 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 27.18% year-over-year to $157.8 million in Q1 2026; TTM through Mar 2026 was $157.8 million, a 27.18% decrease from a year earlier, with the FY2025 full-year figure at $112.7 million, down 56.73% from the prior year.
• Cash & Current Investments advanced to $157.8 million in Q1 2026 per TNGX's latest filing, from $112.7 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $449.9 million in Q1 2022 and bottomed at $58.8 million in Q3 2025.
• The 5-year median for Cash & Current Investments is $216.7 million (2025), against an average of $219.7 million.
• Biggest YoY gain for Cash & Current Investments was 583.81% in 2022; the steepest drop was 79.98% in 2022.
• Year by year, Cash & Current Investments stood at $60.5 million in 2022, then advanced by 11.08% to $67.2 million in 2023, then soared by 287.39% to $260.5 million in 2024, then tumbled by 56.73% to $112.7 million in 2025, then soared by 40.03% to $157.8 million in 2026.
• Per Business Quant, the three latest TNGX Cash & Current Investments figures stand at $157.8 million (Q1 2026), $112.7 million (Q4 2025), and $58.8 million (Q3 2025).